Luye Pharma's Innovative Anti-Cancer Therapy Lurbinectedin to Benefit Named Patients in Hong Kong

HONG KONG, Jan. 9, 2023 /PRNewswire/ -- Luye Pharma's Innovative Anti-Cancer Therapy Lurbinectedin to Benefit

Related Keywords

China ,Australia ,Japan ,Canada ,Hong Kong ,University Of Hong Kong ,Hong Kong General ,Singapore ,Chinese ,William Van ,Luye Pharma ,Leung Kwong Chuen ,Luye Pharma Group ,Patient Program Of Lurbinectedin ,Abacus Medicine Pharma Services Asia ,Drug Administration ,Abacus Medicine Group ,Luye Pharma International ,Hong Kong Precision Oncology Society ,Prnewswire Luye Pharma Group ,Abacus Medicine Pharma Services ,Patient Program ,Department Of Medicine ,Patient Program In Hong Kong ,Pharma Group ,Named Patient Program ,General Manager ,Abacus Medicine Pharma Services Asia Limited ,Andy Siow ,New Drug Application ,Clinical Oncology ,Clinical Associate Professor ,Chinese University ,Practice Guidelines ,Small Cell Lung Cancer ,Medicine Pharma Services ,Abacus Medicine ,Rev Dis ,Lung Cancer ,Luye Pharmas Innovative Anti Cancer Therapy Lurbinectedin To Benefit ,